Galectin Therapeutics Shares Surge on Positive FDA Meeting, Phase 3 Trial Plans
By Elias Schisgall
Shares of Galectin Therapeutics surged after the company said it was preparing for a Phase 3 trial of its liver disease treatment following a positive meeting with the Food and Drug Administration.
Shares were up 21% to $3.38 in trading midday Tuesday. The stock has fallen 19% this year.
The company said it had received positive feedback from the FDA during a Type C meeting about initiating a Phase 3 trial of belapectin, a drug to treat metabolic dysfunction-associated steatohepatitis cirrhosis and portal hypertension.
"Alignment on the study design, primary endpoint, and regulatory framework provides important clarity, as we advance the program with renewed confidence," Chief Executive Officer Joel Lewis said. "We are initiating preparations for the Phase 3 trial and in parallel are evaluating development pathways alongside potential strategic partnership opportunities."
The company expects to submit a final Phase 3 protocol during the third quarter.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
June 23, 2026 12:14 ET (16:14 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States